| 摘要 |
Methods for assessing the potential efficacy of a DNA-damaging agent as a tumour treatment or for monitoring the efficacy of such treatment by determining promyelocytic leukemia protein nuclear body (PML NB) properties of the tumour are disclosed. PML NB properties, including morphology, number and biochemical composition, of cells or tissue are assessed following exposure to a DNA-damaging agent and compared to corresponding PML NB properties of cells or tissue not exposed to the DNA-damaging agent. The difference, or lack thereof, determines the efficacy of the DNA-damaging agent as a treatment for tumours or monitoring the efficacy of such treatment.
|
